ABCD is setting up a nationwide audit of tirzepatide (Mounjaro) in real clinical use in the UK. The aim will be to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials.

About the ABCD tirzepatide audit

The ABCD audit programme featured at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) which was held on 19-22 March 2025 in Amsterdam, Holland.

Testosterone replacement therapy improves glycaemic control and symptoms in men with type 2 diabetes - the ABCD Worldwide Audit

Authors:

T. Hugh Jones, Karim Haider, Ahmed Haider, Umesh Dashora, Robert E, J. Ryder

Incidence and factors associated with restoration of hypoglycaemia awareness in adults with type 1 diabetes treated with hybrid closed-loop in the United Kingdom: Results from the ABCD audit.

Authors:

Alexandros L Liarakos, Thomas SJ Crabtree, Tomás P Griffin, Yew W Yap, Parth Narendran, Muhammad Ali Karamat, Geraldine Gallen, Sufyan Hussain, Jackie Elliott, Lalantha Leelarathna, Alistair Lumb, Robert EJ Ryder, Pratik Choudhary, Emma G Wilmot on behalf of all ABCD Closed-Loop Pilot audit contributors

Please note this programme is subject to change

We welcome abstracts on any subject relating to Diabetes, Endocrinology and General Medicine, which might be of interest to members of the Association. Authors of accepted abstracts will be invited to display their work in the form of a poster at the meeting on 7th November. Those meeting the criteria for publication will be published on the ABCD and BJD websites.

Two prizes will be awarded: